Integrated Drug Development and Regulatory Framework in the Pharmaceutical

Aditya Bangalore Institute of Pharmacy Education and Research (ABIPER), in collaboration with the Indian Pharmaceutical Association (IPA), Bangalore (Urban) Local Branch, organized a seminar entitled “Integrated Drug Development and Regulatory Framework in the Pharmaceutical Industry.” The session was held at the ABIPER Seminar Hall at 11:00 AM, aimed at providing PharmD and M.Pharm students with a professional perspective on industrial drug cycles.
The event commenced with a welcome address delivered by Dr. Venkatesha, Director of ABIPER. In his opening remarks, he emphasized the importance of bridging the gap between academic curricula and industrial requirements, welcoming the guest speaker and the participating students.
The seminar was facilitated by Dr. Suresh Venkataram, a highly regarded Pharmaceutical Consultant. Dr. Venkataram brought extensive industry experience, offering technical insights into the integration of scientific research with global regulatory standards. Dr. Venkataram initiated the discussion by outlining the strategic importance of India in the global market.

• Market Growth: The Indian market was valued at approximately ₹4.7 lakh crore in 2025 and is projected to expand to ₹10 lakh crore by 2030.
• Global Supply: India currently services more than 200 countries, maintaining its status as a leader in generic drug manufacturing.

The speaker also provided a comprehensive breakdown of the drug development lifecycle, emphasizing the progression from molecular identification to clinical validation:
• Discovery Phase: Target discovery, hit generation, lead identification, and lead optimization.

• Preclinical Evaluation: Laboratory and animal testing to assess fundamental safety and biological activity.
• Clinical Trial Framework:

Phase I:Safety assessment in healthy volunteers.
Phase II: Efficacy assessment and dose optimization in patients.
Phase III: Large-scale trials to confirm effectiveness and monitor adverse reactions.

Detailed attention was given to the filing of Investigational New Drug (IND) and New Drug Application (NDA) protocols. Dr. Venkataram also addressed the high-stakes nature of the industry, noting that the average R&D cost exceeds $1.5 billion per drug with a development timeline of 8–10 years. Furthermore, the seminar covered critical formulation parameters, including:

• Physicochemical considerations: Salt selection, polymorphism, and nucleation.
• Manufacturing properties: Powder flow and drug acceptance criteria.
• Dosage selection: Tablets, capsules, ointments, and transdermal systems.

The event concluded with a high-engagement Q&A session. Dr. Venkatesha, Director of ABIPER, delivered the vote of thanks, expressing gratitude to the guest speaker for his time and to the IPA Bangalore (Urban) Local Branch for their collaboration in making the event a success. The seminar successfully enhanced the participants’ understanding of the complex intersection between scientific research and market approval.